Arcus Biosciences Gestione
Gestione criteri di controllo 2/4
Arcus Biosciences Il CEO è Terry Rosen, nominato in May2015, e ha un mandato di 9.5 anni. la retribuzione annua totale è $ 10.12M, composta da 6.4% di stipendio e 93.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.08% delle azioni della società, per un valore di $ 54.85M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 4.7 anni.
Informazioni chiave
Terry Rosen
Amministratore delegato
US$10.1m
Compenso totale
| Percentuale dello stipendio del CEO | 6.4% |
| Mandato del CEO | 9.5yrs |
| Proprietà del CEO | 4.1% |
| Durata media del management | 4.3yrs |
| Durata media del Consiglio di amministrazione | 4.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking
Nov 21
Arcus Biosciences: Advancing On Several Fronts
Oct 29Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
Sep 23Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business
Aug 19Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 15Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts
May 13Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money
May 10We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$270m |
| Jun 30 2024 | n/a | n/a | -US$249m |
| Mar 31 2024 | n/a | n/a | -US$231m |
| Dec 31 2023 | US$10m | US$650k | -US$307m |
| Sep 30 2023 | n/a | n/a | -US$293m |
| Jun 30 2023 | n/a | n/a | -US$287m |
| Mar 31 2023 | n/a | n/a | -US$279m |
| Dec 31 2022 | US$9m | US$350k | -US$267m |
| Sep 30 2022 | n/a | n/a | US$80m |
| Jun 30 2022 | n/a | n/a | US$67m |
| Mar 31 2022 | n/a | n/a | US$58m |
| Dec 31 2021 | US$9m | US$367k | US$53m |
| Sep 30 2021 | n/a | n/a | -US$278m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$168m |
| Dec 31 2020 | US$6m | US$326k | -US$123m |
| Sep 30 2020 | n/a | n/a | -US$88m |
| Jun 30 2020 | n/a | n/a | -US$112m |
| Mar 31 2020 | n/a | n/a | -US$95m |
| Dec 31 2019 | US$2m | US$340k | -US$85m |
| Sep 30 2019 | n/a | n/a | -US$80m |
| Jun 30 2019 | n/a | n/a | -US$69m |
| Mar 31 2019 | n/a | n/a | -US$54m |
| Dec 31 2018 | US$1m | US$295k | -US$50m |
| Sep 30 2018 | n/a | n/a | -US$51m |
| Jun 30 2018 | n/a | n/a | -US$63m |
| Mar 31 2018 | n/a | n/a | -US$59m |
| Dec 31 2017 | US$427k | US$315k | -US$53m |
Compensazione vs Mercato: La retribuzione totale di Terry ($USD 10.12M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.54M ).
Compensazione vs guadagni: La retribuzione di Terry è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Terry Rosen (64 yo)
9.5yrs
Mandato
US$10,120,945
Compensazione
Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 9.5yrs | US$10.12m | 4.08% $ 54.8m | |
| Co- Founder & President | 9.5yrs | US$4.75m | 1.56% $ 21.0m | |
| Principal Financial Officer & CFO | 4.3yrs | US$3.59m | 0.017% $ 227.2k | |
| Chief Operating Officer | 4.1yrs | US$4.74m | 0.082% $ 1.1m | |
| Chief Medical Officer | 2.3yrs | US$3.69m | 0.022% $ 296.8k | |
| Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| VP of Finance & Principal Accounting Officer | 1.7yrs | Nessun dato | 0.0032% $ 43.5k | |
| Chief Scientific Officer | 3.8yrs | Nessun dato | Nessun dato | |
| General Counsel & Corporate Secretary | 6.3yrs | US$2.92m | 0.052% $ 704.2k | |
| Vice President of Corporate Communications | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Human Resources & Operations | no data | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 5.4yrs | Nessun dato | Nessun dato |
4.3yrs
Durata media
52yo
Età media
Gestione esperta: Il team dirigenziale di RCUS è considerato esperto (durata media dell'incarico 4.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 9.6yrs | US$10.12m | 4.08% $ 54.8m | |
| Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Lead Independent Director | 9.5yrs | US$503.21k | 0.16% $ 2.1m | |
| Independent Director | 7.2yrs | US$479.08k | 0.16% $ 2.2m | |
| Independent Director | 3.9yrs | US$455.83k | 0.023% $ 307.7k | |
| Chairman of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 4.9yrs | US$455.83k | 0.018% $ 248.5k | |
| Independent Director & Member of Scientific Advisory Board | 4.5yrs | US$500.83k | 0.054% $ 724.0k | |
| Independent Director & Member of Scientific Advisory Board | 9.8yrs | US$470.83k | 0.033% $ 448.4k | |
| Director | 4.3yrs | Nessun dato | Nessun dato | |
| Independent Director | 3.3yrs | US$450.83k | 0.015% $ 206.2k | |
| Member of Scientific Advisory Board | 4.2yrs | Nessun dato | Nessun dato |
4.7yrs
Durata media
63.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RCUS sono considerati esperti (durata media dell'incarico 4.7 anni).